IRCLSep 6, 2017

Semi-Supervised Recurrent Neural Network for Adverse Drug Reaction Mention Extraction

arXiv:1709.01687v151 citations
Originality Incremental advance
AI Analysis

This work addresses pharmacovigilance monitoring from social media, an incremental improvement for public health applications.

The paper tackles the problem of extracting Adverse Drug Reaction (ADR) mentions from social media, specifically Twitter, by proposing a semi-supervised RNN model that leverages unlabeled data to address labeled data scarcity, achieving state-of-the-art performance.

Social media is an useful platform to share health-related information due to its vast reach. This makes it a good candidate for public-health monitoring tasks, specifically for pharmacovigilance. We study the problem of extraction of Adverse-Drug-Reaction (ADR) mentions from social media, particularly from twitter. Medical information extraction from social media is challenging, mainly due to short and highly information nature of text, as compared to more technical and formal medical reports. Current methods in ADR mention extraction relies on supervised learning methods, which suffers from labeled data scarcity problem. The State-of-the-art method uses deep neural networks, specifically a class of Recurrent Neural Network (RNN) which are Long-Short-Term-Memory networks (LSTMs) \cite{hochreiter1997long}. Deep neural networks, due to their large number of free parameters relies heavily on large annotated corpora for learning the end task. But in real-world, it is hard to get large labeled data, mainly due to heavy cost associated with manual annotation. Towards this end, we propose a novel semi-supervised learning based RNN model, which can leverage unlabeled data also present in abundance on social media. Through experiments we demonstrate the effectiveness of our method, achieving state-of-the-art performance in ADR mention extraction.

Foundations

The foundational work for this paper's niche, ranked by how specifically the neighbourhood builds on it — not by global fame.

Your Notes